Solid Q1 and Guidance Underlines Why Danaher Corporation (DHR) is one of Steve Cohen’s Large-Cap Stock Picks

Danaher Corporation (NYSE:DHR) is one of billionaire Steve Cohen’s large-cap banal picks with the highest upside potential. On May 11, Masimo Corporation reported first‑quarter earnings, apt 1 of its past standalone results earlier being acquired by Danaher Corporation (NYSE:DHR) successful a $9.9 cardinal currency woody astatine $180 per share. Analysts expected $1.43 EPS connected $398.65 cardinal revenue, marking a turnaround from the anterior quarter’s loss. While gross dipped somewhat owed to seasonality, profitability was seen arsenic a cardinal awesome of operational stableness during the merger reappraisal period.

For investors, the absorption is squarely connected Danaher. The acquisition, approved by Masimo shareholders connected May 1, is acceptable to adjacent successful the 2nd fractional of 2026 pending regulatory clearance. Danaher values Masimo’s technologies highly, seeing beardown strategical benefits successful merging its pulse oximetry and diligent monitoring solutions with Danaher’s diagnostics portfolio.

A cleanable 4th strengthens assurance that Masimo volition integrate smoothly into Danaher’s Diagnostics segment, portion immoderate operational missteps could rise concerns astir execution risk. Ultimately, the woody highlights Danaher’s propulsion to grow its healthcare exertion footprint with high‑margin, innovative monitoring solutions.

On April 21, Danaher Corp delivered coagulated first-quarter 2026 results and issued guidance that signals continued maturation momentum successful the year.

Revenue successful the 4th was up 3.5% twelvemonth implicit twelvemonth to $6 billion, arsenic nett net came successful astatine $1 billion, oregon $1.45 per diluted share. Adjusted net per diluted stock grew 9.5% to $2.06. The better-than-expected results came arsenic the squad executed good astatine the backmost of a dependable betterment successful Bioprocessing and better-than-expected show successful Life Sciences.

For the 2nd quarter, Danaher Corp. absorption expects non-GAAP halfway gross maturation successful the debased azygous digits, with full-year maturation betwixt 3% and 6%. The institution has besides accrued its adjusted diluted net per communal stock guidance to $8.35 to $8.55, up from its erstwhile guidance of $8.35 to $8.50.

The institution is besides looking to get Masimo Corporation to further fortify its prospects successful mission-critical pulse oximetry and diligent monitoring solutions successful acute attraction settings.

Danaher Corporation (NYSE:DHR) is simply a planetary subject and exertion innovator that designs, manufactures, and markets products successful beingness sciences, diagnostics, and biology & applied solutions. They service industries specified arsenic biotechnology, healthcare, and h2o prime with tools including analytical instruments, consumables, reagents, and diagnostic software.